Genomic analyses identify molecular subtypes of pancreatic cancer
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Integrated genomic analysis of 456 pancreatic ductal adenocarcinomas identified 32 recurrently mutated genes that aggregate into 10 pathways: KRAS, TGF-β, WNT, NOTCH, ROBO/SLIT signalling, G1/S transition, SWI-SNF, chromatin modification, DNA repair and RNA processing. Expression analysis defined 4 subtypes: (1) squamous; (2) pancreatic progenitor; (3) immunogenic; and (4) aberrantly differentiated endocrine exocrine (ADEX) that correlate with histopathological characteristics. Squamous tumours are enriched for TP53 and KDM6A mutations, upregulation of the TP63∆N transcriptional network, hypermethylation of pancreatic endodermal cell-fate determining genes and have a poor prognosis. Pancreatic progenitor tumours preferentially express genes involved in early pancreatic development (FOXA2/3, PDX1 and MNX1). ADEX tumours displayed upregulation of genes that regulate networks involved in KRAS activation, exocrine (NR5A2 and RBPJL), and endocrine differentiation (NEUROD1 and NKX2-2). Immunogenic tumours contained upregulated immune networks including pathways involved in acquired immune suppression. These data infer differences in the molecular evolution of pancreatic cancer subtypes and identify opportunities for therapeutic development.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“KRAS G12D mutations are most commonly observed in pancreatic ductal adenocarcinoma (36%, [20]) and colorectal cancers (12%, [21]) and are also found in lung, endometrial and other cancers.”
From Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor (2022) · cites this paper as [20]
In the citing paper
“Importantly, a study conducted genomic analyses on pancreatic cancer, involving 456 tumors primarily of PDAC and its variants. The research identified 32 significantly mutated genes grouped into 10 molecular mechanisms, including KRAS mutations in 92% of cases.”
From Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer (2024) · cites this paper as [87]
In the citing paper
“The majority of KRAS mutations are at codon 12, with the highest prevalence of G12D mutation (35%), followed by G12V (20–30%), G12R (10–20%), Q61 (~5%), G12C (1–2%), and other rare muations9–12.”
From Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma (2024) · cites this paper as [11]
In the citing paper
“Amongst these are four canonical mutations – KRAS (~85%), TP53 (60–70%), CDKN2A (>50%), and SMAD4 (~50%).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [51]
In the citing paper
“the genomic landscape of PDAC is also dominated by loss of function alterations of TP53, SMAD4 (also known as DPC4), and CDKN2A45,48–50.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [50]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364
WGCNA: an R package for weighted correlation network analysis
Langfelder, P., & Horvath, S. (2008) · BMC Bioinformatics · doi:10.1186/1471-2105-9-559 · Cited by 27,252
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
Liao, Y., Smyth, G. K., & Shi, W. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt656 · Cited by 27,219
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
GSVA: gene set variation analysis for microarray and RNA-Seq data
Hänzelmann, S., Castelo, R., & Guinney, J. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-7 · Cited by 15,440
Inferring tumour purity and stromal and immune cell admixture from expression data
Yoshihara, K., Shahmoradgoli, M., Martínez, E., Vegesna, R., Kim, H., Torres-Garcia, W., Treviño, V., Shen, H., Laird, P. W., Levine, D. A., et al. (2013) · Nature Communications · doi:10.1038/ncomms3612 · Cited by 9,778
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
Cited by
Items 601–700 of 1,020
Chikhladze, S., Lederer, A., Kousoulas, L., Reinmuth, M., Sick, O., Fichtner‐Feigl, S., & Wittel, U. A. (2019) · World Journal of Surgical Oncology · doi:10.1186/s12957-019-1732-3 · Cited by 60
Lenkiewicz, E., Malasi, S., Hogenson, T. L., Flores, L. F., Barham, W. J., Phillips, W. J., Roesler, A. S., Chambers, K. R., Rajbhandari, N., Hayashi, A., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0078 · Cited by 64
Sunami, Y., Häußler, J., & Kleeff, J. H. (2020) · Cancers · doi:10.3390/cancers12123770 · Cited by 69
“3 months for the squamous subtype) [73].”
Hacking Pancreatic Cancer: Present and Future of Personalized Medicine
Federico, A. D., Tateo, V., Parisi, C., Formica, F., Carloni, R., Frega, G., Rizzo, A., Ricci, D., Marco, M. D., Palloni, A., et al. (2021) · Pharmaceuticals · doi:10.3390/ph14070677 · Cited by 71
“Currently, and considering the available knowledge on PC biology and targeted therapies, almost 25% of PC patients may be a candidate for precision medicine [13].”
BackgroundNeutrophil in the Pancreatic Tumor Microenvironment
Jin, L., Kim, H. S., & Shi, J. (2021) · Biomolecules · doi:10.3390/biom11081170 · Cited by 66
“PDACs can be subtyped into squamous, aberrantly differentiated endocrine exocrine, pancreatic progenitor, and immunogenic subsets based on transcriptomic data [49].”
BackgroundJain, A., & Bhardwaj, V. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i39.6527 · Cited by 75
Overcoming therapy resistance in pancreatic cancer: New insights and future directions
Espona‐Fiedler, M., Patthey, C., Lindblad, S., Sarró, I., & Öhlund, D. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116492 · Cited by 71
“1A) [5].”
Sano, M., Driscoll, D. R., Jesus-Monge, W. E. D., Quattrochi, B., Appleman, V. A., Ou, J., Zhu, L. J., Yoshida, N., Yamazaki, S., Takayama, T., et al. (2016) · Neoplasia · doi:10.1016/j.neo.2016.11.004 · Cited by 64
Shuai, W., Wu, J., Chen, S., Liu, R., Ye, Z., Kuang, C., Fu, X., Wang, G., Li, Y., Peng, Q., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.02.023 · Cited by 61
Self-citationA rationally designed NRP1-independent superagonist SEMA3A mutant is an effective anticancer agent
Gioelli, N., Maione, F., Camillo, C., Ghitti, M., Valdembri, D., Morello, N., Darche, M., Zentilin, L., Cagnoni, G., Qiu, Y., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aah4807 · Cited by 59
Saung, M. T., Muth, S., Ding, D., Thomas, D. L., Blair, A. B., Tsujikawa, T., Coussens, L., Jaffee, E. M., & Zheng, L. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0435-6 · Cited by 59
Proteomic and genomic profiling of pancreatic cancer
Ansari, D., Torén, W., Zhou, Q., Hu, D., & Andersson, R. E. (2019) · Cell Biology and Toxicology · doi:10.1007/s10565-019-09465-9 · Cited by 65
Somerville, T. D. D., Xu, Y., Wu, X., Maia-Silva, D., Hur, S. K., de Almeida, L. M. N., Preall, J. B., Koo, P. K., & Vakoc, C. R. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1921484117 · Cited by 63
“In two additional independent transcriptome studies of human PDA tumors (13, 36), we validated high levels of ZBED2 expression in 16 to 20% of primary patient samples (Fig.”
BackgroundResultInfluentialKandimalla, R., Tomihara, H., Banwait, J. K., Yamamura, K., Singh, G. P., Baba, H., & Goel, A. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-4044 · Cited by 62
“Clin Cancer Res; 26(14) July 15, 2020 CLINICAL CANCER RESEARCH 3644”
BackgroundMethodInfluentialAhmed, A. A., Angell, R. M., Oxenford, S. J., Worthington, J., Williams, N., Barton, N., Fowler, T. G., O’Flynn, D. E., Sunose, M., McConville, M., et al. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00317 · Cited by 62
Self-citationMichl, P., Löhr, M. J., Neoptolemos, J. P., Capurso, G., Rebours, V., Malats, N., Ollivier, M., & Ricciardiello, L. (2021) · United European Gastroenterology Journal · doi:10.1002/ueg2.12123 · Cited by 62
Prospective observational study on biomarkers of response in pancreatic ductal adenocarcinoma
Jiang, L., Qin, J., Dai, Y., Zhao, S., Zhan, Q., Cui, P., Ren, L., Wang, X., Zhang, R., Gao, C., et al. (2024) · Nature Medicine · doi:10.1038/s41591-023-02790-x · Cited by 65
“Over the past few decades, integrated analysis of genomic and transcriptomic data has unveiled the molecular landscape of PDAC, including the identification of key genetic alterations (such as KRAS , TP53 , CDKN2A and SMAD4 ) and expression-based molecular subtypes 9–11, 46, 47 .”
Sun, W., Luan, S., Qi, C., Tong, Q., Yan, S., Li, H., & Zhang, Y. (2019) · Cell Communication and Signaling · doi:10.1186/s12964-019-0425-4 · Cited by 61
Current Strategies and Future Perspectives for Precision Medicine in Pancreatic Cancer
Regel, I., Mayerle, J. V., & Mukund, M. U. (2020) · Cancers · doi:10.3390/cancers12041024 · Cited by 68
“In addition, the APGI consortium genetically classified one of the largest PDAC cohort into four molecular tumor subtypes, which we described above [9].”
BackgroundMethodInfluentialDNA Mismatch Repair Deficiency and Immune Checkpoint Inhibitors in Gastrointestinal Cancers
Bañobre, J. R., & Goel, A. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.11.071 · Cited by 62
Curia, M. C., Fantini, F., Lattanzio, R., Tavano, F., Mola, F. D., Piantelli, M., Battista, P., Sebastiano, P. D., & Cama, A. (2019) · BMC Cancer · doi:10.1186/s12885-019-5616-2 · Cited by 60
Targeting the undruggable in pancreatic cancer using nano-based gene silencing drugs
Kokkinos, J., Ignacio, R. M. C., Sharbeen, G., Boyer, C. A., Gonzales‐Aloy, E., Goldstein, D., Initiative, A. P. C. G., McCarroll, J. A., & Phillips, P. A. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2019.119742 · Cited by 67
Self-citationTomihara, H., Carbone, F., Perelli, L., Huang, J. K.-L., Soeung, M., Rose, J. L., Robinson, F. S., Lissanu, Y., Feng, N., Takeda, M., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-19-3922 · Cited by 66
Self-citationMyeloid Cell Mediated Immune Suppression in Pancreatic Cancer
Kemp, S. B., Pasca di Magliano, M., & Crawford, H. C. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.07.006 · Cited by 55
MDICC: novel method for multi-omics data integration and cancer subtype identification
Yang, Y., Tian, S., Qiu, Y., Zhao, P., & Zou, Q. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac132 · Cited by 60
Faraoni, E. Y., Singh, K., Chandra, V., Roux, O. L., Dai, Y., Şahin, İ., O’Brien, B. J., Strickland, L. N., Li, L., Vucic, E., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-2553 · Cited by 67
“Venn diagram analysis Differentially expressed genes between immunogenic versus squamous and classic versus basal subtypes were obtained from (21) and TCGA (Supplementary Table S1; GUID: 3DD81EAF-3FD448CE-A9DA-2454820DAB10; ref.”
Loveless, I. M., Kemp, S. B., Hartway, K. M., Mitchell, J. T., Wu, Y., Zwernik, S. D., Salas-Escabillas, D. J., Brender, S. M., George, M., Makinwa, Y., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-2183 · Cited by 68
“Some PDAC tumor cells express markers of both subtypes, suggesting that the cells exist on a spectrum of subtype states, with inherent plasticity allowing them to interconvert (17, 32–34).”
Tumor immune microenvironment in pancreatic ductal adenocarcinoma revisited – Exploring the “Space”
Bräutigam, K., Skok, K., Szymoński, K., Rift, C. V., & Karamitopoulou, E. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217699 · Cited by 66
Proteomic analyses identify prognostic biomarkers for pancreatic ductal adenocarcinoma
Hu, D., Ansari, D., Pawłowski, K., Zhou, Q., Sasor, A., Welinder, C., Kristl, T., Bauden, M. P., Rezeli, M., Jiang, Y., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.23929 · Cited by 61
The BRG1/SOX9 axis is critical for acinar cell–derived pancreatic tumorigenesis
Tsuda, M., Fukuda, A., Roy, N., Hiramatsu, Y., Leonhardt, L., Kakiuchi, N., Hoyer, K., Ogawa, S., Goto, N., Ikuta, K., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci94287 · Cited by 70
Veenstra, V. L., Damhofer, H., Waasdorp, C., van Rijssen, L. B., van de Vijver, M. J., Dijk, F., Wilmink, H. W., Besselink, M. G., Busch, O. R., Chang, D. K.-F., et al. (2018) · Oncogenesis · doi:10.1038/s41389-018-0096-9 · Cited by 63
Self-citationA Systems Approach to Refine Disease Taxonomy by Integrating Phenotypic and Molecular Networks
Zhou, X., Lei, L., Liu, J. H., Halu, A., Zhang, Y., Li, B., Guo, Z., Liu, G., Sun, C., Loscalzo, J., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.04.002 · Cited by 60
Chen, C., Xiao, W., Huang, L., Yu, G., Ni, J., Yang, L., Wan, R., & Hu, G. (2017) · PubMed · Cited by 66
Alors‐Pérez, E., Blázquez‐Encinas, R., Alcalá, S., Viyuela-García, C., Pedraza‐Arévalo, S., Herrero‐Aguayo, V., Jiménez‐Vacas, J. M., Mafficini, A., Sánchez‐Frías, M., Cano, M. T., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02153-9 · Cited by 57
“Gene expression data were downloaded from public Array Express database [E-MTAB-1791] [22], GSE15471 [19], “The Cancer Genome Atlas” (TCGA) using cBioPortal (PanCancer Atlas) [5], and GSE79670 [23].”
BackgroundMethodInfluentialSelf-citationDe novo compartment deconvolution and weight estimation of tumor samples using DECODER
Peng, X. L., Moffitt, R. A., Torphy, R. J., Volmar, K. E., & Yeh, J. J. (2019) · Nature Communications · doi:10.1038/s41467-019-12517-7 · Cited by 65
Leibowitz, B. D., Dougherty, B. V., Bell, J. S. K., Kapilivsky, J., Michuda, J., Sedgewick, A. J., Munson, W., Chandra, T. A., Dry, J. R., Beaubier, N. T., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-09669-z · Cited by 66
“Our observed prevalence of BRCA -deficiency in prostate and pancreatic cancers is 6.5% and 2.4%, which is similar to the values reported by others: 6.2% and 3.4% respectively (51,52).”
InfluentialKumarasamy, V. M., Frangou, C. G., Wang, J., Wan, Y., Dynka, A., Rosenheck, H. R., Dey, P., Abel, E. V., Knudsen, E. S., & Witkiewicz, A. K. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-2504 · Cited by 63
KRAS: the Achilles’ heel of pancreas cancer biology
Drizyte‐Miller, K., Talabi, T., Somasundaram, A., Cox, A. D., & Der, C. J. (2025) · Journal of Clinical Investigation · doi:10.1172/jci191939 · Cited by 73
Ghanat Bari, M., Ung, C. Y., Zhang, C., Zhu, S., & Li, H. (2017) · Scientific Reports · doi:10.1038/s41598-017-07481-5 · Cited by 56
Evaluation of circulating tumor DNA as a biomarker in pancreatic cancer with liver metastasis
Uesato, Y., Sasahira, N., Ozaka, M., Sasaki, T., Takatsuki, M., & Zembutsu, H. (2020) · PLoS ONE · doi:10.1371/journal.pone.0235623 · Cited by 60
Long noncoding RNA lncHand2 promotes liver repopulation via c-Met signaling
Wang, Y., Zhu, P., Wang, J., Zhu, X., Luo, J., Meng, S., Wu, J., Ye, B., He, L., Du, Y., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.029 · Cited by 63
Self-citationVogl, U. M., Andalibi, H., Klaus, A., Vormittag, L., Schima, W., Heinrich, B., Kafka, A., Winkler, T., & Öhler, L. (2019) · BMC Cancer · doi:10.1186/s12885-018-5240-6 · Cited by 55
“carry rat sarcoma (RAS) or tumour protein (TP)53 mutations, which make pancreatic cancer unsuitable for precision medicine with targeted agents [16].”
BackgroundNF-κB and Pancreatic Cancer; Chapter and Verse
Silke, J., & O’Reilly, L. A. (2021) · Cancers · doi:10.3390/cancers13184510 · Cited by 57
“PDAC is resistant to all traditional forms of cancer therapies, possibly due to the high abundance of molecular alterations [27,28,30,102,147,230].”
BackgroundCombinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy
Li, E., Huang, X., Zhang, G., & Liang, T. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02055-w · Cited by 61
KDM6 Demethylases and Their Roles in Human Cancers
Hua, C., Chen, J., Li, S., Zhou, J., Fu, J., Sun, W., & Wang, W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.779918 · Cited by 60
Exploring the Clinical Utility of Pancreatic Cancer Circulating Tumor Cells
Yeo, D., Bastian, A., Strauss, H., Saxena, P., Grimison, P., & Rasko, J. E. J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031671 · Cited by 61
Fan, X., Lü, P., Wang, H., Bian, S., Wu, X., Zhang, Y., Liu, Y., Fu, D., Wen, L., Hao, J., et al. (2022) · Cell Discovery · doi:10.1038/s41421-021-00366-y · Cited by 64
Wedge, M.-È., Jennings, V. A., Crupi, M. J. F., Poutou, J., Jamieson, T. R., Pelin, A., Pugliese, G., de Souza, C. T., Petryk, J., Laight, B. J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29526-8 · Cited by 60
The interactive role of inflammatory mediators and metabolic reprogramming in pancreatic cancer
Ohara, Y., Valenzuela, P., & Hussain, S. P. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.03.004 · Cited by 60
Qiu, S., Zhang, A., Zhang, T., Sun, H. J., Guan, Y., Yan, G., & Wang, X. (2017) · Oncotarget · doi:10.18632/oncotarget.21897 · Cited by 55
“Genomics gives an overview of the complete set of genetic information about phenotype [5].”
BackgroundHolst, S., Belo, A. I., Giovannetti, E., van Die, I., & Wuhrer, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-16811-6 · Cited by 54
Circulating tumour cells and DNA as liquid biopsies in gastrointestinal cancer
Nordgård, O., Tjensvoll, K., Gilje, B., & Søreide, K. (2018) · British journal of surgery · doi:10.1002/bjs.10782 · Cited by 62
Mueller, J. J., Schlappe, B. A., Kumar, R., Olvera, N., Dao, F., Abu‐Rustum, N. R., Aghajanian, C. A., DeLair, D. F., Hussein, Y. R., Soslow, R. A., et al. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.05.008 · Cited by 63
“Comparison with high-grade serous ovarian, colorectal, gastric and pancreatic carcinomas The mutational frequencies of the 341 genes in our targeted sequencing panel of MOCs were compared to those of HGSOCs from The Cancer Genome Atlas (TCGA; n=316) [29], mucinous colorectal carcinomas (TCGA; n=32) [30], mucinous gast…”
BackgroundResultInfluentialFujikura, K., Akita, M., Ajiki, T., Fukumoto, T., Itoh, T., & Zen, Y. (2018) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001155 · Cited by 58
Molecular alterations associated with metastases of solid pseudopapillary neoplasms of the pancreas
Amato, E., Mafficini, A., Hirabayashi, K., Lawlor, R. T., Fassan, M., Vicentini, C., Barbi, S., Delfino, P., Sikora, K. O., Rusev, B. C., et al. (2018) · The Journal of Pathology · doi:10.1002/path.5180 · Cited by 57
Self-citationStrijker, M., Chen, J., Mungroop, T. H., Jamieson, N. B., van Eijck, C. H. J., Steyerberg, E. W., Wilmink, J. W., Koerkamp, B. G., van Laarhoven, H. W. M., & Besselink, M. G. (2019) · British journal of surgery · doi:10.1002/bjs.11111 · Cited by 61
Self-citationGendoo, D. M. A., Denroche, R. E., Zhang, A. X. W., Radulovich, N., Jang, G. H., Lemire, M., Fischer, S. E., Chadwick, D. E., Lungu, I. M., Ibrahimov, E., et al. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006596 · Cited by 64
CT radiomics associations with genotype and stromal content in pancreatic ductal adenocarcinoma
Attiyeh, M. A., Chakraborty, J., McIntyre, C. A., Kappagantula, R., Chou, Y., Askan, G., Seier, K., Gonen, M., Basturk, O., Balachandran, V. P., et al. (2019) · Abdominal Radiology · doi:10.1007/s00261-019-02112-1 · Cited by 55
Self-citationBazzichetto, C., Luchini, C., Conciatori, F., Vaccaro, V., Cello, I. D., Mattiolo, P., Falcone, I., Ferretti, G., Scarpa, A., Cognetti, F., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228841 · Cited by 59
“In 2016, a large study including 456 pancreatic cancer patients classified these tumors into four subtypes according to a comprehensive integrated genomic and transcriptomic analysis; very interestingly, these subtypes are associated with specific histopathological characteristics [7].”
BackgroundSelf-citationClinical Trials of Systemic Chemotherapy for Resectable Pancreatic Cancer: A Review
Mavros, M. N., Moris, D., Karanicolas, P. J., Katz, M. H. G., O'Reilly, E. M., & Pawlik, T. M. (2021) · JAMA Surgery · doi:10.1001/jamasurg.2021.0149 · Cited by 58
Progress in Animal Models of Pancreatic Ductal Adenocarcinoma
Kong, K., Guo, M., Liu, Y., & Zheng, J. (2020) · Journal of Cancer · doi:10.7150/jca.37529 · Cited by 65
“Genetic mutations highly correlated with this process have been reported in the literatures [4].”
BackgroundSpatiotemporal dynamics of self-organized branching in pancreas-derived organoids
Randriamanantsoa, S., Papargyriou, A., Maurer, H. C., Peschke, K., Schuster, M., Zecchin, G., Steiger, K., Öllinger, R., Saur, D., Scheel, C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32806-y · Cited by 65
LAMC2 marks a tumor-initiating cell population with an aggressive signature in pancreatic cancer
Cave, D. D., Buonaiuto, S., Sáinz, B., Fantuz, M., Mangini, M., Carrer, A., Domenico, A. D., Iavazzo, T. T., Andolfi, G., Cortina, C., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02516-w · Cited by 58
Hyeon, D. Y., Nam, D., Han, Y., Kim, D. K., Kim, G., Kim, D., Bae, J., Back, S., Mun, D., Madar, I. H., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00479-7 · Cited by 59
“1e): 10 from The Cancer Genome Atlas (TCGA)10, 22 from Bailey et al.11, 16 from Biankin et al.12, 4 from Waddell et al.13 and 6 from Witkiewicz et al.14.”
MethodGenomic signatures of pancreatic adenosquamous carcinoma (PASC)
Fang, Y., Su, Z., Xie, J., Xue, R., Ma, Q., Li, Y., Zhao, Y., Song, Z., Lu, X., Li, H., et al. (2017) · The Journal of Pathology · doi:10.1002/path.4943 · Cited by 54
“utilized transcriptional profiles to distinguish their PC patients (PDAC ∼90%) by four histopathological characteristics, whereby the squamous subtype was enriched for TP53/KDMA6 mutations [6].”
BackgroundMethodA mechanopharmacology approach to overcome chemoresistance in pancreatic cancer
Coppola, S., Carnevale, I., Danen, E. H. J., Peters, G. J., Schmidt, T., Assaraf, Y. G., & Giovannetti, E. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.07.001 · Cited by 60
Validation and comparison of the molecular classifications of pancreatic carcinomas
Birnbaum, D. J., Finetti, P., Birnbaum, D., Mamessier, É., & Bertucci, F. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0739-z · Cited by 63
“Finally, we defined the molecular subtype of each sample in each data set separately as defined in the original publications: the three Collisson’s subtypes [4], the two Moffitt’s “tumor-specific subtypes” [5], the two Moffitt’s “stroma subtypes” [5], and the four Bailey’s subtypes [6].”
BackgroundMethodLucien, F., Lac, V., Billadeau, D. D., Borgida, A., Gallinger, S., & Leong, H. S. (2019) · Oncotarget · doi:10.18632/oncotarget.26620 · Cited by 55
Use of Biomarkers and Imaging for Early Detection of Pancreatic Cancer
Kato, S., & Honda, K. (2020) · Cancers · doi:10.3390/cancers12071965 · Cited by 61
“Multiple independent sequencing analyses involving a large number of PDAC patients showed similar results, with approximately 90% of PDACs carrying at least one KRAS mutation [94,95].”
ResultTopham, J. T., Karasinska, J. M., Lee, M. K. C., Csizmók, V., Williamson, L., Jang, G. H., Denroche, R. E., Tsang, E. S., Kalloger, S. E., Wong, H., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2831 · Cited by 65
“Bailey subtyping was based on genes from differential expression analysis results from the original publication (6), which were filtered for genes with an adjusted P < 0.”
MethodResultGendoo, D. M. A. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.01.010 · Cited by 53
“As a larger encompassing ‘omics platform, whole-genome sequencing has been used to assess the genomic complexity of resected PDAC tumours [37,41-43], and has shed light on complex genomic events, such as catastrophic mitotic phenomena (chromothripsis) that occur with high frequency [43].”
BackgroundTIMP1 expression underlies sex disparity in liver metastasis and survival in pancreatic cancer
Hermann, C. D., Schoeps, B., Eckfeld, C., Munkhbaatar, E., Kniep, L., Prokopchuk, O., Wirges, N., Steiger, K., Häußler, D., Knolle, P. A., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20210911 · Cited by 56
Pre-clinical Models of Metastasis in Pancreatic Cancer
Miquel, M., Zhang, S., & Pilarsky, C. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.748631 · Cited by 53
Self-citationPoh, A. R., & Ernst, M. (2023) · Oncogene · doi:10.1038/s41388-023-02701-x · Cited by 60
“Activating mutations in KRAS are a hallmark of pancreatic cancer, and are observed in approximately 95% of patients [41, 42].”
BackgroundNew Developments in the Molecular Mechanisms of Pancreatic Tumorigenesis
Felsenstein, M., Hruban, R. H., & Wood, L. D. (2017) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000172 · Cited by 64
Self-citationSalt-Inducible Kinase 2: An Oncogenic Signal Transmitter and Potential Target for Cancer Therapy
Chen, F., Chen, L., Qin, Q., & Sun, X. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00018 · Cited by 57
Immunophenotypes of pancreatic ductal adenocarcinoma: Meta‐analysis of transcriptional subtypes
de Santiago, I., Yau, C., Heij, L. R., Middleton, M. R., Markowetz, F. M., Grabsch, H. I., Dustin, M. L., & Sivakumar, S. (2019) · International Journal of Cancer · doi:10.1002/ijc.32186 · Cited by 53
“demonstrated 4 subtypes with different characterisations and different prognoses: ‘squamous’, ‘pancreatic progenitor’, ‘immunogenic’ and ‘aberrantly differentiated endocrine exocrine’ (ADEX).(7) Sivakumar et al.”
BackgroundParkin, A., Man, J., Timpson, P., & Pajic, M. (2019) · FEBS Journal · doi:10.1111/febs.15011 · Cited by 58
Self-citationHuang, C., You, X., Dai, C., Xu, Q., Li, F., Wang, L., Huang, X., Wang, J., Li, S., Gao, Z., et al. (2020) · Advanced Science · doi:10.1002/advs.201902926 · Cited by 51
Self-citationZhou, Q., Bauden, M. P., Andersson, R. E., Hu, D., Marko‐Varga, G., Xu, J., Sasor, A., Dai, H., Pawłowski, K., Hilmersson, K. S., et al. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02254-7 · Cited by 62
Higashijima, Y., Matsui, Y., Shimamura, T., Nakaki, R., Nagai, N., Tsutsumi, S., Abe, Y., Link, V. M., Osaka, M., Yoshida, M., et al. (2020) · The EMBO Journal · doi:10.15252/embj.2019103949 · Cited by 64
Mechanisms Governing Immunotherapy Resistance in Pancreatic Ductal Adenocarcinoma
Schmiechen, Z. C., & Stromnes, I. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.613815 · Cited by 68
“These results are consistent with a putative immunogenic subset based on transcriptional profiling (12) and indicate that T cells are present in a fraction of human tumors.”
BackgroundResultPTHrP Drives Pancreatic Cancer Growth and Metastasis and Reveals a New Therapeutic Vulnerability
Pitarresi, J. R., Norgard, R. J., Chiarella, A. M., Suzuki, K., Bakir, B. S., Sahu, V., Li, J., Zhao, J., Marchand, B., Wengyn, M. D., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1098 · Cited by 61
“[3], which revealed that PTHLH mRNA was significantly enriched in the squamous subset relative to other subtypes (Figure 2D).”
BackgroundSelf-citationZhou, Z., Zhang, J., Xu, C., Yang, J., Zhang, Y., Liu, M., Shi, X., Li, X., Zhan, H., Chen, W., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103271 · Cited by 60
“Currently, several molecular classification systems have been proposed in PDAC, including the Moffitt subtypes [10], Collisson subtypes [11], and Bailey subtypes [12].”
BackgroundHNF1A inhibition induces the resistance of pancreatic cancer cells to gemcitabine by targeting ABCB1
Lu, Y., Xu, D., Peng, J., Luo, Z., Chen, C., Chen, Y., Chen, H., Zheng, M., Yin, P., & Wang, Z. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.05.013 · Cited by 55
“, we surmised that HNF1Amay functiondifferently in different diseases, even in differentmolecule subtypes of pancreatic cancer [32].”
BackgroundMaina, S., Donovan, N. J., Plett, K. L., Bogema, D. R., & Rodoni, B. (2024) · Frontiers in Horticulture · doi:10.3389/fhort.2024.1388028 · Cited by 69
“This approach has been widely exploited in plant transcriptome sequencing, generating accurate and reproducible datasets (e.g. Levin et al., 2010; Bailey et al., 2016).”
MethodTargeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges
Choucair, K., Imtiaz, H., Uddin, M. H., Nagasaka, M., Al-Hallak, M. N., Philip, P. A., El-Rayes, B., Pasche, B., & Azmi, A. S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02473-8 · Cited by 80
“124,126 While mostly characterized in NSCLC, understanding the impact of co-occurring mutations and alterations, along with KRAS, is important not only for potential prognostication but also for developing potential therapeutic interventions.”
Sivakumar, S., de Santiago, I., Chlon, L., & Markowetz, F. M. (2017) · PLoS Medicine · doi:10.1371/journal.pmed.1002223 · Cited by 53
Epithelial-Myeloid cell crosstalk regulates acinar cell plasticity and pancreatic remodeling in mice
Zhang, Y., Yan, W., Mathew, E., Kane, K. T., Brannon, A., Adoumie, M., Vinta, A., Crawford, H. C., & Pasca di Magliano, M. (2017) · eLife · doi:10.7554/elife.27388 · Cited by 52
“Kras mutations are common in human pancreatic cancer (Bailey et al., 2016; Hezel et al., 2006; Jones et al., 2008), and are present with high frequency in the precursor lesions to pancreatic cancer known as Pancreatic Intraepithelial Neoplasia (PanIN) (Kanda et al., 2012; Klimstra and Longnecker,…”
BackgroundWu, Q., Tian, Y., Zhang, J., Zhang, H., Gu, F., Lu, Y., Zou, S., Chen, Y., Sun, P., Xu, M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.21970 · Cited by 56
Extracellular Influences: Molecular Subclasses and the Microenvironment in Pancreatic Cancer
Veenstra, V., Garcia-Garijo, A., Van Laarhoven, H., & Bijlsma, M. (2018) · Cancers · doi:10.3390/cancers10020034 · Cited by 52
“High purity Low purity Bailey [32] Stroma normal Stroma activated Common subtypes Other subtypes”
BackgroundMethodInfluentialTakeuchi, S., Doi, M., Ikari, N., Yamamoto, M., & Furukawa, T. (2018) · Scientific Reports · doi:10.1038/s41598-018-26526-x · Cited by 52
Entrectinib in TRK and ROS1 Fusion-Positive Metastatic Pancreatic Cancer
Pishvaian, M. J., Garrido‐Laguna, I., Liu, S. V., Multani, P. S., Chow‐Maneval, E., & Rolfo, C. D. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00039 · Cited by 53
Current State of “Omics” Biomarkers in Pancreatic Cancer
Turanlı, B., Yildirim, E., Gülfidan, G., Arğa, K. Y., & Sinha, R. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11020127 · Cited by 56
“In light of the rapidly developing accuracy and efficiency of proteomic approaches, our knowledge of the underlying molecular mechanism of pancreatic cancer has greatly increased [104,105].”
BackgroundEpigenetic Alterations in Pancreatic Cancer Metastasis
Wang, S. S., Xu, J., Ji, K. Y., & Hwang, C. (2021) · Biomolecules · doi:10.3390/biom11081082 · Cited by 56
“For example, given that at least 18% of PDA patient carries KDM6A mutations [7], which are associated with the squamous molecular subtype, Andricovich et al. found that loss of KDM6A in PDA can directly induce the squamous identity by upregulating the expressions of specific TF encoding genes, including p63, ZEB1, RUN…”
BackgroundInfluentialA 25-gene classifier predicts overall survival in resectable pancreatic cancer
Birnbaum, D. J., Finetti, P., Lopresti, A., Gilabert, M., Poizat, F., Raoul, J.-L., Delpero, J.-R., Moutardier, V., Birnbaum, D., Mamessier, E., et al. (2017) · BMC Medicine · doi:10.1186/s12916-017-0936-z · Cited by 51
“Biologically relevant molecular subtypes have been identified [16, 25, 26], and associated with OS [27].”
InfluentialCui, J., Quan, M., Xie, D., Gao, Y., Guha, S., Fallon, M. B., Chen, J., & Xie, K. (2020) · Oncogene · doi:10.1038/s41388-019-1051-8 · Cited by 55
NOX4: a potential therapeutic target for pancreatic cancer and its mechanism
Bi, Y., Lei, X., Chai, N., & Linghu, E. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-03182-w · Cited by 61
Proteogenomic insights into the biology and treatment of pancreatic ductal adenocarcinoma
Tong, Y., Sun, M., Chen, L., Wang, Y., Yan, L., Li, L., Zhang, X., Cai, Y., Qie, J., Pang, Y., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01384-3 · Cited by 57
“Table S2F Matrix of the 10 mutated genes used in Figure 1C of TCGA, 2018 cohort.”
BackgroundMethodResultInfluentialYang, S., Tang, W., Azizian, A., Gaedcke, J., Ströbel, P., Wang, L., Cawley, H., Ohara, Y., Valenzuela, P., Zhang, L., et al. (2022) · Carcinogenesis · doi:10.1093/carcin/bgac092 · Cited by 57
Metadata
- Authors
- Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., Nourse, C., Murtaugh, L. C., Harliwong, I., Idrisoglu, S., Manning, S., Nourbakhsh, E., Wani, S., Fink, L., Holmes, O., Chin, V., Anderson, M. J., Kazakoff, S., Leonard, C., Newell, F., Waddell, N., Wood, S., Xu, Q., Wilson, P. J., Cloonan, N., Kassahn, K. S., Taylor, D., Quek, K., Robertson, A., Pantano, L., Mincarelli, L., Sanchez, L. N., Evers, L., Wu, J., Pinese, M., Cowley, M. J., Jones, M. D., Colvin, E. K., Nagrial, A. M., Humphrey, E. S., Chantrill, L. A., Mawson, A., Humphris, J., Chou, A., Pajic, M., Scarlett, C. J., Pinho, A. V., Giry-Laterriere, M., Rooman, I., Samra, J. S., Kench, J. G., Lovell, J. A., Merrett, N. D., Toon, C. W., Epari, K., Nguyen, N. Q., Barbour, A., Zeps, N., Moran-Jones, K., Jamieson, N. B., Graham, J. S., Duthie, F., Oien, K., Hair, J., Grützmann, R., Maitra, A., Iacobuzio-Donahue, C. A., Wolfgang, C. L., Morgan, R. A., Lawlor, R. T., Corbo, V., Bassi, C., Rusev, B., Capelli, P., Salvia, R., Tortora, G., Mukhopadhyay, D., Petersen, G. M., Initiative, A. P. C. G., Munzy, D. M., Fisher, W. E., Karim, S. A., Eshleman, J. R., Hruban, R. H., Pilarsky, C., Morton, J. P., Sansom, O. J., Scarpa, A., Musgrove, E. A., Bailey, U.-M. H., Hofmann, O., Sutherland, R. L., Wheeler, D. A., Gill, A. J., Gibbs, R. A., Pearson, J. V., Waddell, N., Biankin, A. V., & Grimmond, S. M.
- Affiliations
- The University of Queensland (AU)
- Garvan Institute of Medical Research (AU)
- Baylor College of Medicine (US)
- University of Utah (US)
- South Australia Pathology (AU)
- Harvard University (US)
- University of Glasgow (GB)
- Camden and Campbelltown Hospitals (AU)
- The University of Sydney (AU)
- UNSW Sydney (AU)
- Fiona Stanley Hospital (AU)
- Royal Adelaide Hospital (AU)
- Princess Alexandra Hospital (AU)
- The University of Western Australia (AU)
- Glasgow Royal Infirmary (GB)
- Beatson West of Scotland Cancer Centre (GB)
- NHS Greater Glasgow and Clyde (GB)
- Southern General Hospital (GB)
- Technische Universität Dresden (DE)
- The University of Texas MD Anderson Cancer Center (US)
- Johns Hopkins University (US)
- University of Verona (IT)
- Mayo Clinic (US)
- Cancer Research UK Scotland Institute (GB)
- Corresponding author
- Biankin, Andrew V.
- Grimmond, Sean M.
- ORCID
- Bailey, Peter
- Chang, David K.
- Johns, Amber L.
- Patch, Ann-Marie
- Gingras, Marie-Claude
- Christ, Angelika N.
- Quinn, Michael C.
- Murtaugh, L. Charles
- Harliwong, Ivon
- Manning, Suzanne
- Nourbakhsh, Ehsan
- Wani, Shivangi
- Holmes, Oliver
- Chin, Venessa
- Anderson, Matthew J.
- Kazakoff, Stephen
- Leonard, Conrad
- Newell, Felicity
- Wood, Scott
- Wilson, Peter J.
- Cloonan, Nicole
- Kassahn, Karin S.
- Quek, Kelly
- Robertson, Alan
- Pantano, Lorena
- Mincarelli, Laura
- Wu, Jianmin
- Pinese, Mark
- Cowley, Mark J.
- Jones, Marc D.
- Colvin, Emily K.
- Nagrial, Adnan M.
- Chantrill, Lorraine A.
- Mawson, Amanda
- Chou, Angela
- Pajic, Marina
- Scarlett, Christopher J.
- Pinho, Andreia V.
- Rooman, Ilse
- Samra, Jaswinder S.
- Kench, James G.
- Merrett, Neil D.
- Toon, Christopher W.
- Nguyen, Nam Q.
- Barbour, Andrew
- Zeps, Nikolajs
- Jamieson, Nigel B.
- Graham, Janet S.
- Oien, Karin
- Grützmann, Robert
- Maitra, Anirban
- Wolfgang, Christopher L.
- Lawlor, Rita T.
- Corbo, Vincenzo
- Bassi, Claudio
- Rusev, Borislav
- Salvia, Roberto
- Tortora, Giampaolo
- Petersen, Gloria M.
- Karim, Saadia A.
- Eshleman, James R.
- Hruban, Ralph H.
- Pilarsky, Christian
- Morton, Jennifer P.
- Sansom, Owen J.
- Scarpa, Aldo
- Bailey, Ulla-Maja Hagbo
- Hofmann, Oliver
- Wheeler, David A.
- Gill, Anthony J.
- Gibbs, Richard A.
- Pearson, John V.
- Waddell, Nicola
- Biankin, Andrew V.
- Grimmond, Sean M.
- Venue
- Nature
- Published
- 2016-02-24
- Volume
- 531
- Issue
- 7592
- Pages
- 47-52
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2285093314
- Cited by
- 3,621
- References
- 52
- Citations by year
- 2026: 247 · 2025: 347 · 2024: 311 · 2023: 404 · 2022: 430 · 2021: 504 · 2020: 397 · 2019: 307 · 2018: 295 · 2017: 257 · 2016: 117
- FWCI
- 175.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- eSpace (Curtin University) (submittedVersion)
- Minerva Access (University of Melbourne) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- NOVA (University of Newcastle Australia) (submittedVersion)
- Funders
- Pancreatic Cancer UK (RIF2015_A06_Jamieson)
- Wellcome Trust (103721/Z/14/Z)
- Cancer Research UK (C29717/A17263, A12481, 17263, A18076, 12946, 20409, 11650, 21139, 22533)
- Academy of Medical Sciences (AMS-SGCL9-Jamieson)
- Medical Research Council (MR/N005813/1)
- National Cancer Institute (P50CA062924)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- pancreatic ductal adenocarcinoma, molecular subtypes, recurrent mutations, KRAS, TP53, p63, KDM6A, DNA methylation, pancreatic progenitor cells, endocrine differentiation, immunosuppression, prognosis, transcriptional regulatory networks, histopathology
- MeSH terms
- Homeobox Protein Nkx-2.2, Animals, DNA-Binding Proteins, Humans, Mutation, Nuclear Proteins, Pancreatic Neoplasms, Prognosis, Transcription Factors, Transcription, Genetic, Trans-Activators, Genome, Human, Gene Expression Regulation, Neoplastic, Survival Analysis, Tumor Suppressor Protein p53, Receptors, Cytoplasmic and Nuclear, Homeodomain Proteins, DNA Methylation, Carcinoma, Pancreatic Ductal, Genomics, Tumor Suppressor Proteins, Zebrafish Proteins, Cell Line, Tumor, Mice, Hepatocyte Nuclear Factor 3-beta, Hepatocyte Nuclear Factor 3-gamma, Basic Helix-Loop-Helix Proteins, Genes, Neoplasm, Gene Regulatory Networks, Histone Demethylases, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.